760,993 Shares in ImmunityBio, Inc. $IBRX Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 760,993 shares of the company’s stock, valued at approximately $6,662,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sigma Planning Corp lifted its position in shares of ImmunityBio by 7.3% during the 2nd quarter. Sigma Planning Corp now owns 19,015 shares of the company’s stock valued at $166,000 after acquiring an additional 1,300 shares during the period. Mariner LLC raised its stake in ImmunityBio by 10.5% in the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock valued at $35,000 after purchasing an additional 1,689 shares in the last quarter. Sanctuary Advisors LLC raised its stake in ImmunityBio by 6.9% in the fourth quarter. Sanctuary Advisors LLC now owns 29,547 shares of the company’s stock valued at $59,000 after purchasing an additional 1,918 shares in the last quarter. Sequoia Financial Advisors LLC lifted its position in ImmunityBio by 8.6% during the fourth quarter. Sequoia Financial Advisors LLC now owns 28,783 shares of the company’s stock worth $57,000 after purchasing an additional 2,271 shares during the period. Finally, Archer Investment Corp lifted its position in ImmunityBio by 67.1% during the first quarter. Archer Investment Corp now owns 5,872 shares of the company’s stock worth $45,000 after purchasing an additional 2,358 shares during the period. 8.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on IBRX. BTIG Research reissued a “buy” rating and issued a $12.00 target price on shares of ImmunityBio in a report on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Friday, July 10th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.20.

Insider Transactions at ImmunityBio

In other news, Director Cheryl Cohen sold 131,210 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total value of $1,246,495.00. Following the sale, the director directly owned 125,386 shares in the company, valued at approximately $1,191,167. This trade represents a 51.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christobel Selecky sold 159,478 shares of ImmunityBio stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $9.02, for a total transaction of $1,438,491.56. Following the sale, the director directly owned 35,064 shares in the company, valued at $316,277.28. This trade represents a 81.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 412,410 shares of company stock valued at $3,753,442. 66.10% of the stock is currently owned by insiders.

ImmunityBio Stock Down 4.2%

Shares of IBRX stock opened at $7.72 on Friday. ImmunityBio, Inc. has a twelve month low of $1.95 and a twelve month high of $12.43. The company has a market cap of $8.18 billion, a P/E ratio of -7.96 and a beta of 0.04. The business has a fifty day simple moving average of $7.82 and a 200 day simple moving average of $7.89.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.70 million. As a group, equities research analysts anticipate that ImmunityBio, Inc. will post -0.44 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies and other treatments designed to activate the immune system against cancer and infectious diseases. The company’s platform combines biologics, cell therapies, vaccines and other approaches intended to generate durable immune responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.